Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Pacritinib in Refractory Chronic Graft-Versus-Host Disease (cGVHD)
NCT05531786Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in chronic graft-versus-host disease (cGVHD), sponsored by National Cancer Institute. Started Mar 2023; status: recruiting.
02
Drugs
pacritinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05531786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531786.